F circulating testosterone. Androgen Rolipram 61413-54-5 deprivation therapy is not only cytostatic but also cytotoxic to hormone-sensitive prostate cancer and thus a strong regulator of survival and tumor growth. GnRH agonists are still the most common form of ADT. Agonists stimulate initially Highest hypophys Ren GnRH receptors, resulting in a rapid release of gonadotropins and testosterone, the start of the ADT-plated Siege and has triggered rare clinical complications such as obstruction of the bladder outlet associated and an increased pain or compression the spinal cord in patients with metastatic disease. To avoid such complications, should GnRH agonists in patients at high risk may be administered with an antiandrogen to block the effects at the level of testosterone receptors. In contrast, GnRH antagonists quickly block the production of testosterone, the peak of testosterone and thus to avoid the administration of antiandrogens cooperation. The efficacy of these two treatment regimens in reducing the total volume of the prostate has not been systematically compared. In almost 70% of patients with prostate cancer, the disease comes from the peripheral zone of the prostate and the cause of the symptoms My R Umlichkeiten only if they compress or invade the north He learned how structures prostatic urethral Hre, bladder or neurovaskul Ren bundle. Another, h More often, by h Here LUTS in patients Fulvestrant Estrogen/progestin receptor inhibitor with prostate cancer is the parallel growth of the prostate due to BPH, which cause the take Shows prevalence with age. Gem Lehrer et al. , 55.6% of patients with prostate cancer have no symptoms are mild, 37.1% symptom My moderate, and 7.3% have symptoms My grave. There is still little information from randomized clinical trials on the effects of ADT on short-term LUTS and whether GnRH analogues, agonists and antagonists have anything similar in this respect useful. The aim of this study was to evaluate and compare the effect of 12 weeks of therapy with submission of degarelix with monthly goserelin acetate implant 1 month, with a focus on reducing TPV, relieving LUTS and Ver Changes in the Lebensqualit t associated with symptoms my urine. Materials and Methods This study was a randomized, controlled parallel arm Lee, open, multicenter study. Inclusion criteria were: 18 years, histologically trust RMED PCa patients suitable for ADT with a serum PSA screening at 2 ng / ml, 30 ml of TPV, a bone scan in the last 12 weeks, and a business PROTECTED life expectancy of at least 12 months . Ned protocol defined exclusion criteria were already back U treatments for prostate cancer, the use of a catheter into the bladder during the treatment to be expected with an inhibitor of 5-reductase, or botulinum toxin in the last 6 months of treatment with alpha-adrenergic blocker in the last 4 weeks, or radiation w Of the process . Patients who U at least one dose of study medication and again at least one evaluation after the administration had been effi ciency in the Full Analysis Set. The per-protocol population was obtained by excluding major protocol violators. The study was conducted in accordance with the Declaration of Helsinki and guidelines for good clinical practice. Local or regional ethics committees and institutional review boards approved the protocol. Eligible patients were randomized to receive either treatment with degarelix or monthly.